Clinical Associate Professor, Psychiatry
Faculty of Medicine
UBC â€“ BCMHARI
Phone: 604-875-2000 ext 4722
Email: [email protected]
Description of Research Program
My research interests are primarily in the psychopharmacology of schizophrenia. Some of my current projects include:
- antipsychotic polypharmacy in which we are studying prevalence, predictors, indicators and clinical outcomes associated with this relatively common prescribing practice that is not adequately supported by the literature or clinical practice guidelines;
- smoking and schizophrenia where we have and continue to investigate the relationship between tobacco consumption and antipsychotic treatment, self-reported motivations for why individuals with schizophrenia smoke, and predictors of starting to smoke in first episode patients;
- the influence of serum lipids on clozapine’s clinical efficacy in which we are exploring possible mechanism(s) that underlie our previous work showing a positive correlation between serum triglycerides and clinical response to clozapine; and
- the metabolic effects of antipsychotics where we are investigating the acute and chronic effects of the atypical antipsychotics on alterations in glucose and insulin parameters.
Mental Illness / Substance
Antipsychotics, Schizophrenia, Tobacco
Area of Research
Antipsychotic polypharmacy, Clinical trials, Smoking and schizophrenia
Antipsychotic associated dyslipidemia, Antipsychotic polypharmacy, Pharmacoeconomics, Pharmacokinetics, Psychopharmacology
View Complete List of Publications
Procyshyn RM, Barr AM, Flynn S, Schenk C, Ganesan S, Ko R, Honer WG. Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. Schizophrenia Research (In Press)
Procyshyn RM, Honer WG, Wu TKY, Ko RWY, McIsaac SA, Young AH, Johnson JL, Barr AM. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting. Journal of Clinical Psychiatry 2010;71:566-573.
Procyshyn RM, Barr AM, Brickell T, Honer WG. Medication errors in Psychiatry: A comprehensive review. CNS Drugs 2010;24:595-609.
Procyshyn RM, Honer WG, Barr AM. Do serum lipids predict response to clozapine treatment? Psychopharmacology for the Clinician. Journal of Psychiatry and Neuroscience 2009;34:168.
Barr AM, Procyshyn RM, Hui P, Johnson J, Honer WG. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophrenia Research 2008;100:252-260.
Procyshyn RM, Wasan K, Thornton AE, Barr AM, Chen EYH, Stip E, Williams R, MacEwan GW, Birmingham CL, Honer WG. Changes in Serum Lipids, Independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Journal of Psychiatry and Neuroscience 2007;32:331-338.